Chiesi Archives -

A new study has suggested that the economic burden posed by rare diseases is around 10 times higher

Rare diseases have tenfold higher impact on healthcare costs; study

https://pharmaphorum.com/news/rare-diseases-have-tenfold-higher-impact-on-healthcare-costs-study/

Sales and Marketing/ Views & Analysis/ Views and analysis

The benefits of being a family-run pharma company

mike.hammerton@pharmaphorum.com Chiesi, Rare diseases 0 Comment

The third generation of his family to hold a leadership role at Chiesi Group, Giacomo Chiesi reflects on

The benefits of being a family-run pharma company

https://pharmaphorum.com/sales-marketing/chiesi-family-run-pharma-company-benefits/

News/ News/ R&D

Switch data back Chiesi/Protalix long-acting Fabry drug

Phil Taylor Chiesi, Fabrazyme, Fabry disease, Protalix, rare disease, Replagal, Sanofi Genzyme, Takeda 0 Comment

Chiesi and Protalix have built the case for their long-acting enzyme replacement therapy (ERT) for Fabry disease PRX-102,

Switch data back Chiesi/Protalix long-acting Fabry drug

https://pharmaphorum.com/news/switch-data-back-chiesi-protalix-long-acting-fabry-drug/

News/ News/ R&D

Moderna broadens R&D scope with Vertex, Chiesi alliances

Phil Taylor Chiesi, cystic fibrosis, Moderna, partnership, pulmonary arterial hypertension, Vertex Pharma 0 Comment

All eyes may be on Moderna’s COVID-19 vaccine at the moment, but the US biotech hasn’t been idle

Moderna broadens R&D scope with Vertex, Chiesi alliances

https://pharmaphorum.com/news/moderna-broadens-rd-scope-with-vertex-chiesi-alliances/

Market Access/ News/ News/ Top stories

Chiesi’s flagship Fabry drug heads for FDA verdict in early 2021

Phil Taylor Chiesi, Fabry disease, Protalix, rare disease 0 Comment

The FDA has started its review of Israeli biotech Protalix BioTherapeutics and partner Chiesi’s Fabry disease therapy pegunigalsidase

Chiesi’s flagship Fabry drug heads for FDA verdict in early 2021

https://pharmaphorum.com/news/chiesis-flagship-fabry-drug-heads-for-fda-verdict-in-early-2021/

R&D/ Views & Analysis/ Views and analysis

Chiesi ups its focus on rare diseases

Richard Staines Chiesi, Rare diseases 0 Comment

Italy’s Chiesi has created a new business unit aimed at increasing its presence in the market for rare

Chiesi ups its focus on rare diseases

https://pharmaphorum.com/r-d/views-analysis-r-d/chiesi-ups-its-focus-on-rare-diseases/

News/ News/ R&D

Chiesi starts rare diseases division, ahead of potential Fabry disease filing

Richard Staines Chiesi, Fabry disease, Protalix, R&D, Rare diseases, respiratory, Takeda 0 Comment

Italian pharma Chiesi has begun a new rare diseases division as it builds towards a potential commercial launch

Chiesi starts rare diseases division, ahead of potential Fabry disease filing

https://pharmaphorum.com/news/chiesi-starts-rare-diseases-division-as-fabry-treatment/

Market Access/ News/ News

FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSK

Phil Taylor AstraZeneca, Chiesi, COPD, GlaxoSmithKline, respiratory 0 Comment

The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by

FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSK

https://pharmaphorum.com/news/fda-rejection-scuppers-azs-hopes-of-a-copd-triple-clash-with-gsk/

GlaxoSmithKline/ Market Access/ News/ News/ News/ R&D/ R&D/ UK & Europe

Verona to take COPD hopeful into phase 3

Richard Staines Chiesi, COPD, GlaxoSmithKline, R&D, respiratory 0 Comment

Verona Pharma is to take lung drug RPL554 into late clinical development after a successful phase 2b trial.

Verona to take COPD hopeful into phase 3

https://pharmaphorum.com/market-access-2/verona-to-take-copd-hopeful-into-phase-3/

Trending

Chiesi

Login